Combined Oral Contraceptive vs Nurtec ODT (Rimegepant): Which One Is Right for You?

What These Two Drugs Actually Do, and Why Women Compare Them

These two medications almost never appear in the same prescription conversation. COCs are hormonal drugs that suppress ovulation, reduce circulating androgens, and stabilize the endocrine environment of the menstrual cycle. Rimegepant blocks the calcitonin gene-related peptide (CGRP) receptor, a pathway that drives migraine pain and neurogenic inflammation. The two drugs work through completely separate mechanisms and are approved for different indications.

Women end up comparing them for one specific, real-world reason: hormonal migraine. A significant proportion of women with migraine experience attacks that cluster around menstruation, driven by the estrogen withdrawal that occurs in the late luteal phase. Some clinicians have historically tried to smooth that estrogen drop with extended-cycle or low-placebo-interval COCs. Rimegepant, approved by the FDA for both acute treatment and prevention of episodic migraine, offers a hormone-free alternative for that same population.

The framework that matters here is not "which drug is better overall" but "which drug fits this woman's specific hormonal status, migraine type, and reproductive goals." This article works through that question systematically, by life stage and condition.

No direct randomized head-to-head trial comparing COCs with rimegepant for any shared indication exists in the published literature as of early 2025. The comparisons below are synthesized across separate, high-quality trials and are labeled as indirect comparisons throughout.

How COCs Work in Women's Bodies

Combined oral contraceptives suppress the hypothalamic-pituitary-ovarian axis by delivering exogenous estrogen and progestin, preventing the LH surge that triggers ovulation. The estrogen component, almost always ethinyl estradiol (EE) in modern pills, also suppresses hepatic sex-hormone-binding globulin (SHBG) production to varying degrees depending on progestin type, which directly affects free androgen levels circulating in your blood.

What the COC Does to Your Hormone Environment

The net hormonal effect of a COC depends on which progestin is paired with EE. Drospirenone has anti-androgenic and anti-mineralocorticoid properties. Norgestimate and desogestrel are relatively androgen-neutral. Levonorgestrel and norethindrone have mild androgenic activity and may worsen acne in androgen-sensitive women. This distinction matters when you are choosing a COC for PCOS or hormonal acne versus purely for contraception.

COC Efficacy in PCOS and Androgen-Driven Conditions

A 2011 systematic review covering 46 randomized trials of COCs in women with PCOS found that COC use significantly reduced total testosterone, free androgen index, and LH-to-FSH ratio compared with baseline, while improving cycle regularity. The review confirmed that all combined pills improved menstrual regularity, with differences between formulations most apparent for skin outcomes. Pills containing cyproterone acetate (available outside the US) produced the largest androgen reductions. For women with PCOS managing hirsutism, acne, or irregular cycles, COCs remain the ACOG-endorsed first-line pharmacologic option when contraception is also desired.

Rimegepant has no published data in PCOS populations. It has no effect on androgens, cycle regulation, or ovulation. For a woman whose primary concern is PCOS-related hormone imbalance, rimegepant is not a relevant option.

How Rimegepant Works, and What the Trial Data Show

Rimegepant is a small-molecule CGRP receptor antagonist taken as a 75 mg orally disintegrating tablet. CGRP is released from trigeminal nerve terminals during a migraine attack and is one of the central mediators of migraine pain. Unlike older triptans, rimegepant does not cause vasoconstriction, which is clinically important for women with cardiovascular risk factors or migraine with aura.

The Lancet 2021 Prevention Trial

The Lancet 2021 randomized, double-blind, placebo-controlled trial of rimegepant for migraine prevention enrolled 348 adults with 4 to 14 migraine days per month. Participants took rimegepant 75 mg every other day. The primary endpoint was the change from baseline in mean monthly migraine days across weeks 9 to 12.

Rimegepant reduced monthly migraine days by a mean of 4.3 days versus 3.5 days for placebo, a statistically significant difference (p = 0.0099). Roughly 49% of participants on rimegepant achieved at least a 50% reduction in monthly migraine days compared with 41% for placebo. The drug was well tolerated, with nausea the most commonly reported adverse event at around 2% of participants.

What the Trial Did Not Tell Us

The Lancet 2021 trial did not stratify results by menstrual cycle phase, hormonal contraceptive use, or menopausal status. The proportion of women in the trial was approximately 88%, typical for migraine research, but sex-specific subgroup analyses were not published in the primary paper. This is a meaningful evidence gap for women trying to understand whether rimegepant works differently across the cycle.

The Overlap Zone: Hormonal Migraine

This is where the comparison between COCs and rimegepant becomes clinically real.

What Hormonal Migraine Actually Is

Menstrually related migraine affects an estimated 60% of women who have migraine, with attacks most likely to occur in the two days before and three days after menstruation onset. The mechanism is the sharp drop in estrogen at the end of the luteal phase, which triggers CGRP release and trigeminal sensitization. These menstrual attacks tend to be longer, more severe, and more resistant to acute treatment than non-menstrual attacks.

Can a COC Help Hormonal Migraine?

In theory, eliminating the estrogen drop through continuous or extended-cycle COC use should reduce menstrual migraine frequency. In practice, the evidence is mixed. Some women find that low-dose EE pills worsen migraine during the hormone-free interval because even a small estrogen withdrawal provokes attacks. Others benefit from extended-cycle regimens that limit that interval to four times per year.

For women with migraine without aura, COCs are generally considered acceptable with appropriate counseling. For women with migraine with aura, the WHO Medical Eligibility Criteria for Contraceptive Use assigns a Category 4 (unacceptable health risk) classification to combined hormonal contraceptives, because the combination raises ischemic stroke risk substantially. This is not a relative contraindication. It is an absolute one.

Rimegepant as a Hormone-Free Option for Menstrual Migraine

For a woman who has migraine with aura and cannot use COCs, or who finds that hormonal manipulation worsens her migraine pattern, rimegepant offers a completely hormone-free approach to both acute treatment and prevention. The every-other-day dosing schedule from the Lancet 2021 trial is one possible route, though clinicians also use it acutely at the first sign of a migraine attack.

Because rimegepant carries no estrogen, it does not increase stroke risk, does not suppress ovulation, and does not interact with the menstrual cycle hormonally. For perimenopausal women whose migraine frequency rises as estrogen levels become erratic, this matters a great deal.

Pregnancy, Lactation, and Contraception: Required Reading

Both drugs require specific pregnancy and lactation guidance. Read this section carefully regardless of your current reproductive plans.

COC in Pregnancy and Lactation

COCs are contraindicated in pregnancy. If you become pregnant while taking a COC, stop the pill immediately. Although early studies raised concern about fetal exposure to synthetic estrogen and progestin, current evidence does not confirm a teratogenic risk from inadvertent first-trimester COC exposure, but discontinuation remains standard care.

During lactation, combined estrogen-containing pills are generally avoided in the first 6 weeks postpartum because estrogen may suppress milk supply. After 6 weeks, low-dose EE pills may be used with monitoring, though ACOG recommends progestin-only options as preferred for breastfeeding women.

Rimegepant in Pregnancy and Lactation

Rimegepant has no adequate, well-controlled studies in pregnant women. Animal reproductive toxicity studies at exposures exceeding the human therapeutic dose showed adverse developmental effects. The FDA labeling recommends avoiding rimegepant during pregnancy.

For lactation, it is unknown whether rimegepant is excreted into human breast milk. Given the lack of data, the prescribing information advises that the developmental and health benefits of breastfeeding should be weighed against the mother's clinical need for the drug and potential infant exposure. A reasonable clinical approach is to pump and discard milk for a period following each dose, though exact timing recommendations are not established in the prescribing label.

Contraception Requirements

COCs themselves are contraception. Women using rimegepant for migraine prevention who do not want pregnancy will need a separate contraceptive method. Rimegepant has no known interactions with hormonal contraceptives at the pharmacokinetic level, but because it is a moderate CYP3A4 substrate, caution is warranted with strong CYP3A4 inhibitors or inducers that might also affect contraceptive metabolism. Discuss your full medication list with your prescriber before starting either drug.

Who This Is Right For, by Life Stage and Condition

Reproductive Years (Ages 18 to 40, Not Trying to Conceive)

A woman in her 20s or 30s with PCOS, hormonal acne, or dysmenorrhea and no migraine with aura is a strong COC candidate. The 2011 PCOS systematic review showed reliable cycle regulation and androgen reduction across all combined formulations.

A woman of the same age who has frequent migraine with aura should not be on a COC and may benefit from rimegepant for both acute treatment and prevention. Her contraceptive needs should be met through a progestin-only pill, IUD, or barrier method.

A woman with migraine without aura and PCOS faces the most complex decision. A COC might help PCOS symptoms but could theoretically alter migraine frequency in either direction depending on the hormone-free interval she uses. Continuous dosing to minimize estrogen withdrawal is one strategy; rimegepant for breakthrough migraine is another tool in the same plan.

Trying to Conceive

Neither drug is appropriate here. COCs prevent pregnancy by design. Rimegepant lacks reproductive-safety data. Women actively trying to conceive who experience migraine should discuss acute options like acetaminophen for mild attacks or whether sumatriptan (better-studied in pregnancy) is appropriate, in consultation with their OB-GYN or neurologist.

Perimenopause (Typically Ages 40 to 52)

This is where rimegepant deserves more attention than it currently receives. Migraine prevalence peaks in women in their late 30s and is often at its most new during perimenopause, when estrogen fluctuates unpredictably. COCs are sometimes used in perimenopausal women for cycle regulation, vasomotor symptom reduction, and contraception, but they carry higher venous thromboembolism and cardiovascular risk in women over 35 who smoke and are not appropriate for all women in this group.

For a perimenopausal woman whose migraine is worsening and who either cannot tolerate or is not a candidate for COCs, rimegepant offers a non-hormonal migraine-specific approach. The Lancet 2021 trial enrolled adults up to approximately 65 years of age, so older perimenopausal women were represented, though menopausal status was not a reported subgroup variable.

Postmenopause

COCs are not used in postmenopausal women. Systemic hormone therapy (low-dose estradiol plus progesterone) may be used for symptom management in this group but is a different drug class entirely. Rimegepant remains an option for postmenopausal women who continue to experience migraine, a group that is under-recognized clinically and under-studied in trials.

Safety Comparison: The Risks Women Need to Know

COC Safety Signals in Women

COCs carry a well-established set of risks that are sex-specific and magnitude-dependent.

• Venous thromboembolism (VTE): The absolute risk of VTE in reproductive-age women not using COCs is roughly 3 to 4 per 10,000 women-years. COC use raises this to approximately 9 to 10 per 10,000 women-years. Drospirenone-containing pills may carry slightly higher VTE risk than levonorgestrel-containing pills, though the absolute difference is small.
• Stroke: Combined hormonal contraceptives roughly double the relative risk of ischemic stroke. In women with migraine with aura, the baseline stroke risk is already elevated, making combined hormonal contraception an unacceptable choice.
• Blood pressure: EE raises blood pressure in a dose-dependent fashion. Women with pre-existing hypertension should have blood pressure controlled before starting a COC.
• Mood: Some women report depressive symptoms on COCs. The largest observational data on this topic, a Danish cohort study of over one million women, found a modest but statistically significant association between hormonal contraceptive use and antidepressant prescription.

Rimegepant Safety Signals

Rimegepant has a substantially different and generally milder safety profile in the published trial data. In the Lancet 2021 prevention trial, adverse events leading to discontinuation were uncommon. Nausea occurred in approximately 2% of participants on active drug. No cardiovascular signals emerged in the trials completed to date.

Because rimegepant lacks vasoconstrictive activity, it is safe to use in women with cardiovascular risk factors who cannot tolerate triptans. Hepatic impairment is a consideration: severe hepatic impairment is listed as a contraindication in the prescribing information because rimegepant is primarily metabolized by CYP3A4 in the liver.

Long-term safety data beyond 52 weeks is limited. Women are, as noted in W6, under-represented in early-phase pharmacokinetic studies for CGRP antagonists, and female-specific PK data for rimegepant are not prominently reported in published Phase 2 and 3 papers. This is an honest evidence gap.

Cost, Access, and Real-World Considerations

COCs are among the most accessible prescription medications in the United States. Under the Affordable Care Act, most insurance plans cover at least one formulation without cost-sharing. Generic formulations are available for most pill types at very low out-of-pocket cost.

Rimegepant (Nurtec ODT) is a branded medication with a list price of approximately $900 to $1,000 for a package of 8 tablets as of 2024. Insurance coverage varies widely. Manufacturer copay assistance programs are available for commercially insured patients and can reduce out-of-pocket cost significantly, but Medicare and Medicaid patients face more restrictions.

For a woman managing menstrual migraine on a tight budget, a COC might be the more accessible option if she is a candidate for it and if hormonal manipulation of her migraine pattern is appropriate. Rimegepant, for a woman who needs it, may require prior authorization documentation from her prescriber.

Indirect Efficacy Comparison: What the Separate Trials Tell Us

No direct head-to-head randomized trial comparing COCs with rimegepant for any shared indication exists. The following is an indirect comparison across separate trials with different designs, populations, and endpoints. Treat it as directional, not definitive.

| Outcome | COC (PCOS/Acne Review, 2011) | Rimegepant (Lancet 2021) | |---|---|---| | Cycle regulation | Effective across all formulations | No effect | | Free androgen reduction | Significant reduction vs baseline | No effect | | Monthly migraine day reduction | Varies; may help or worsen by formulation | 4.3 days vs 3.5 days placebo (p = 0.0099) | | Stroke risk in migraine with aura | Contraindicated (WHO Cat 4) | No increased risk identified | | Pregnancy prevention | Primary indication | None | | Ovulation suppression | Yes | No | | Hormonal side effects | Yes (VTE, mood, blood pressure) | Minimal hormonal effects | | Oral bioavailability | High (EE); varies by progestin | Approximately 64% for rimegepant |

Can You Take Both at the Same Time?

In principle, yes. There is no pharmacodynamic interaction between a COC and rimegepant. A woman with PCOS who uses a COC for cycle regulation and who also experiences episodic migraine could, in theory, use rimegepant acutely for breakthrough migraine attacks.

The practical caveat is drug interaction through the CYP3A4 pathway. Rimegepant is a CYP3A4 substrate, and some progestin formulations are also partially metabolized through this pathway. Strong CYP3A4 inhibitors (like ketoconazole or clarithromycin) can increase rimegepant exposure; strong inducers (like rifampin) can reduce it. The interactions between a standard COC and rimegepant at therapeutic doses are not expected to be clinically significant, but your pharmacist or prescriber should review your full medication list before you start either drug.

Switching Between Them: What You Should Know

If you are currently on a COC for hormonal migraine management and it is not helping or is worsening your migraine, switching to or adding rimegepant is a reasonable clinical conversation to have with your neurologist or gynecologist.

When stopping a COC to transition to a hormone-free migraine regimen, expect a temporary period of cycle irregularity and possible mood fluctuation as your hypothalamic-pituitary-ovarian axis resumes its natural pattern. This typically resolves within one to three cycles. During this window, if you were relying on the COC for contraception, use a barrier method.

Rimegepant reaches steady-state plasma concentrations within a few days of regular dosing in the prevention schedule. You do not need to taper into it. Preventive benefit in the Lancet trial was measurable by weeks 4 to 8.